CCMU
ADMS

Cheyne Capital Management (UK)’s Adamas Pharmaceuticals ADMS Stock Holding History

Cheyne Capital Management (UK)’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-100,000
Closed -$3.39M – 39
2017
Q4 		$3.39M Sell
100,000
-128,837
-56% -$3.6M 1.48% 17
2017
Q3 		$4.84M Buy
228,837
+120,000
+110% +$2.2M 1.75% 15
2017
Q2 		$1.9M Sell
108,837
-5,928
-5% -$98K 0.73% 27
2017
Q1 		$2.01M Sell
114,765
-30,000
-21% -$511K 0.76% 20
2016
Q4 		$2.45M Buy
144,765
+30,000
+26% +$464K 1.38% 11
2016
Q3 		$1.88M Hold
114,765
– – 1.13% 14
2016
Q2 		$1.74M Buy
114,765
+60,000
+110% +$989K 1.4% 8
2016
Q1 		$792K Buy
54,765
+40,000
+271% +$674K 0.26% 24
2015
Q4 		$418K Sell
14,765
-15,235
-51% -$256K 0.23% 26
2015
Q3 		$502K Buy
+30,000
New +$683K 0.24% 32

Other funds holding ADMS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cheyne Capital Management (UK)'s ADMS Position: Q1 2018 in Review

Cheyne Capital Management (UK) sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 100,000 shares — an estimated $3.39M sold.

Cheyne Capital Management (UK) first reported a position in ADMS in Q3 2015 and held it in 10 quarters. The position peaked at $4.84M in Q3 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

  • Cheyne Capital Management (UK) reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Cheyne Capital Management (UK) sold 100,000 Adamas Pharmaceuticals shares in Q1 2018, an estimated $3.39M.
  • Cheyne Capital Management (UK) first reported a position in Adamas Pharmaceuticals in Q3 2015 and held it in 10 quarters.
  • Cheyne Capital Management (UK)'s Adamas Pharmaceuticals position peaked at $4.84M in Q3 2017.
  • 118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Cheyne Capital Management (UK)'s 13F filing for Q1 2018, filed 10 May 2018.